Impact of allopurinol use on urate concentration and cardiovascular outcome

British Journal of Clinical Pharmacology

Volumn 71, Issue 4, 2011, Pages 600-607

  Wei, Li ^a   Mackenzie, Isla S ^a   Chen, Yang ^b   Struthers, Allan D ^a   Macdonald, Thomas M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b GONVILLE AND CAIUS COLLEGE   (United Kingdom)

Author keywords

Allopurinol; Cardiovascular event; Mortality; Urate

Indexed keywords

ALLOPURINOL; COLCHICINE; PROBENECID; SULFINPYRAZONE; URATE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; ALLOPURINOL; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; GOUT; GOUT SUPPRESSANTS; GREAT BRITAIN; HOSPITALIZATION; HUMANS; HYPERURICEMIA; MALE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URIC ACID;

EID: 79952608393     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03887.x     Document Type: Article

References (29)

1. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51: 321-5.
2. Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, Schumacher HR Jr. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28: 577-80.
3. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 356-60.
4. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, García-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57: 545-9.
5. Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, Brouwers JRA. randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009; 68: 892-7.
6. Zoppini G, Targher G, Negri C, Stoico V, Perrone F, Muggeo M, Bonora E. Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. Diabetes Care 2009; 32: 1716-20. Epub 2009 Jun 19.
7. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991-7.
8. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-10.
9. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 2009; 61: 225-32.
10. Niskanen LK, Laaksonen DE, Nyyssönen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546-51.
11. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol Normalizes Endothelial Dysfunction in Type 2 Diabetics with Mild Hypertension. Hypertension 2000; 35: 746-51.
12. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002; 87: 229-34.
13. th edn. ed. Strom BL. Chichester: John Wiley and Sons, 2005; 323-36.
14. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
15. Wei L, Fahey T, Struthers AD, MacDonald TM. Association between Allopurinol and mortality in heart failure patients: a long-term follow-up study. Int J Clin Pract 2009; 63: 1327-33.
16. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006; 58: 87-114.
17. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114: 2508-16. Epub 2006 Nov 27.
18. Short RA, Johnson RJ, Tuttle KR. Uric acid, microalbuminuria and cardiovascular events in high-risk patients. Am J Nephrol 2005; 25: 36-44. Epub 2005 Feb 21.
19. Aengevaeren WR. Beyond lipids - the role of the endothelium in coronary artery disease. Atherosclerosis 1999; 147: (Suppl. 1): S11-6. Review.
20. Noman A, Ang DS, Ogston S, Belch JJ, Struthers A. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010; 375: 2161-7. Epub 2010 Jun 9.
21. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300: 924-32.
22. Luk AJ, Levin GP, Moore EE, Zhou XH, Kestenbaum BR, Choi HK. Allopurinol and mortality in hyperuricaemic patients. Rheumatology 2009; 48: 804-6. Epub 2009 May 15.
23. Zhang W, Doherty M, Pascual E, Zhang W, Doherty M, Pascual E. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301-11. Epub 2006 May 17. Review.
24. Richette P, Bardin T. Gout. Lancet 2010;375: 318-28. Epub 2009 August 17. Review.
25. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006; 33: 1646-50.
26. Muir SW, Harrow C, Dawson J, Lees KR, Weir CJ, Sattar N, Walters MR. Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial. Stroke 2008; 39: 3303-7. Epub 2008 Oct 9.
27. MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, McDevitt DG. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 1333-7.
28. Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. BMJ 1993; 307: 846-8.
29. Scottish health Survey. 2003. Available at (last accessed on 5 January 2011).